NASDAQ:KZIA

US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPG

SYDNEY, Aug. 24, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Kazia's paxalisib (formerl...

2020-08-24 09:14 5488

US FDA Awards Fast Track Designation (FTD) to Paxalisib for Glioblastoma

SYDNEY, Aug. 20, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Kazia's paxalisib (forme...

2020-08-20 08:35 7548

US FDA Grants Rare Pediatric Disease Designation (RPDD) to Paxalisib for DIPG

SYDNEY, Aug. 7, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Rare Pediatric Disease Designation (RPDD) to Kazia's paxalis...

2020-08-07 08:30 12758

Kazia Presents Further Paxalisib and Cantrixil Data at AACR, Reinforcing Positive Efficacy Signals for both Drugs

SYDNEY, June  22, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share poster presentations of interim data from the ongoing phase II study of paxalisib (formerly GDC-0084) in glioblastoma, the most com...

2020-06-22 12:39 3143

Kazia Presents Interim Paxalisib Phase II Data at ASCO Showing Positive Overall Survival Signal

SYDNEY, June 1, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share a poster presentation of interim data from the ongoing phase II study of paxalisib (formerly GDC-0084) in glioblastoma, the most comm...

2020-06-01 08:45 3993

Kazia's Paxalisib Shows Positive Overall Survival Signal in Phase II Glioblastoma Study

SYDNEY, April 7, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share positive interim data from its ongoing phase II study of paxalisib (formerly GDC-0084) in glioblastoma, the most common and most agg...

2020-04-07 20:00 2961

Kazia Initiates Preparatory Activities to Bring GDC-0084 into GBM AGILE, an International Phase II / III Study in Glioblastoma

SYDNEY, Dec. 11, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it's lead program, GDC-0084, has been selected to join GBM AGILE, an international, academic-led, multi-drug adaptive phase ...

2019-12-11 08:41 5450

Positive Interim Efficacy Data from GDC-0084 Phase II Study in Glioblastoma Released at SNO Conference

SYDNEY, Nov. 25, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share with investors interim data from its ongoing phase II study of GDC-0084 in glioblastoma, the most common and most aggressive form of...

2019-11-25 07:00 1347

Kazia Raises A$4.0 Million to Progress R&D Programs

SYDNEY, Oct. 28, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce the completion of a placement of ten million new fully paid ordinary shares in the Company (New Shares) to institutional, profess...

2019-10-28 10:16 6226

Kazia wins ANZLF Trans-Tasman Innovation & Growth Award and reports new data from clinical trial in childhood brain cancer

SYDNEY, Sept. 13, 2019 /PRNewswire/ -- Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) is pleased to announce that it has been named as a winner in the 2019 ANZLF Trans-Tasman Innovation & Growth Awards. The Awards celebrate the innovation, growth and ...

2019-09-13 20:00 6476

St Jude Study of GDC-0084 in DIPG Successfully Completes First Stage; Second Part of Study Now Underway

SYDNEY, Sept. 12, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that St Jude Children's Research Hospital has successfully completed the first stage of its ongoing phase I study of Kazia's in...

2019-09-12 21:10 6831

Kazia to test GDC-0084 with Radiotherapy in Phase I Clinical Trial at Leading US Cancer Center

SYDNEY, July 22, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that Memorial Sloan Kettering Cancer Center (MSK) inNew York, NY will investigate the potential use of Kazia's investigational ne...

2019-07-22 09:08 2332

Kazia calls for greater awareness of the deadliest brain cancer in the US

SYDNEY, July 17, 2019 /PRNewswire/ -- This Glioblastoma Awareness Day, Australian oncology-focused biotech company, Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA), calls for greater awareness of the most lethal brain cancer in the US. Glioblastoma (GBM) is the most common, complex, treatment ...

2019-07-17 20:00 7231

Kazia Enters Clinical Collaboration for Metastatic Brain Cancer with Alliance for Clinical Trials in Oncology

SYDNEY, May 20, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into a collaboration with the Alliance for Clinical Trials in Oncology Foundation (Alliance), a US-based cance...

2019-05-20 11:41 2423

Kazia calls for greater awareness of the deadliest gynecological cancer in the US

SYDNEY, May 8, 2019 /PRNewswire/ -- This World Ovarian Cancer Day, Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) calls for greater awareness of what is the most lethal gynaecological cancer in the US. In 2019, around 22,530 women will receive a new d...

2019-05-08 20:00 5530

Kazia calls for greater awareness of the most lethal women's disease in Australia

SYDNEY, May 8, 2019 /PRNewswire/ -- This World Ovarian Cancer Day, Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) calls for greater awareness of what is the most lethal women's disease in Australia. Every year, approximately 1,600 Australian women are...

2019-05-08 09:55 5444

Kazia Presents Positive Cantrixil Phase I Data at AACR Conference

SYDNEY, April 1, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to provide investors with a poster presentation summarising data from Part A of the ongoing phase I study of Cantrixil (TRX-E-002-1) in ovari...

2019-04-01 11:29 4182

Kazia to present on Cantrixil at American Association for Cancer Research (AACR) 2019 Annual Meeting

SYDNEY, March 25, 2019 /PRNewswire/ -- Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) has been selected to present data from the Phase I study of Cantrixil in ovarian cancer at the American Association for Cancer Research (AACR) 2019 Annual Meeting. A...

2019-03-25 13:25 3925

Kazia Share Purchase Plan Raises A$0.8 Million, Taking Total Funds Raised to A$4.2 Million

SYDNEY, Nov. 20, 2018 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the Share Purchase Plan (SPP), as described in the SPP booklet dated23 October 2018, has now been successfully completed. T...

2018-11-20 12:53 1233

Progress Update on GDC-0084 Program

SYDNEY, Oct. 29, 2018 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to provide an update to shareholders regarding progress with GDC-0084, which is currently in human trials for glioblastoma and several other ...

2018-10-29 18:00 919
12